|
1
|
Hassan A, Mosley J, Singh S and Zinn PO: A
comprehensive review of genomics and noncoding RNA in gliomas. Top
Magn Reson Imaging. 26:3–14. 2017.PubMed/NCBI
|
|
2
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 13l:803–820. 2016. View Article : Google Scholar
|
|
4
|
Brada M, Hoang-Xuan K, Rampling R,
Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA,
Bravo-Marques JM, Henriksson R, et al: Multicenter phase II trial
of temozolomide in patients with glioblastoma multiforme at first
relapse. Ann Oncol. 12:259–266. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Flores DG, Ledur PF, Abujamra AL, Brunetto
AL, Schwartsmann G, Lenz G and Roesler R: Cancer stem cells and the
biology of brain tumors. Curr Stem Cell Res Ther. 4:306–313. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Doherty MR, Smigiel JM, Junk DJ and
Jackson MW: Cancer stem cell plasticity drives therapeutic
resistance. Cancers (Basel). 8:E82016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Batlle E and Clevers H: Cancer stem cells
revisited. Nat Med. 23:1124–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu P and Fan Z: Cancer stem cells and
tumorigenesis. Biophys Rep. 4:178–188. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang PY, Yang YJ, Xue Y, Fu J, Zhang CX,
Wang Y, Yang Y and Shi H: Cancer stem cells: Targeting tumors at
the source. Eur Rev Med Pharmacol Sci. 19:1821–1828.
2015.PubMed/NCBI
|
|
11
|
Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y,
Chang AE and Wicha MS: Concise review: Targeting cancer stem cells
using immunologic approaches. Stem Cells. 33:2085–2092. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmohl JU and Vallera DA: CD133,
selectively targeting the root of cancer. Toxins (Basel).
8:E1652016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jang JW, Song Y, Kim SH, Kim J and Seo HR:
Potential mechanisms of CD133 in cancer stem cells. Life Sci.
184:25–29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beier D, Hau P, Proescholdt M, Lohmeier A,
Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier
CP: CD133+ and CD133- glioblastoma-derived cancer stem cells show
differential growth characteristics and molecular profiles. Cancer
Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem cells in
glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tamura K, Aoyagi M, Ando N, Ogishima T,
Wakimoto H, Yamamoto M and Ohno K: Expansion of CD133-positive
glioma cells in recurrent de novo glioblastomas after radiotherapy
and chemotherapy. J Neurosurg. 119:1145–1155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Niero EL, Rocha-Sales B, Lauand C, Cortez
BA, de Souza MM, Rezende-Teixeira P, Urabayashi MS, Martens AA,
Neves JH and Machado-Santelli GM: The multiple facets of drug
resistance: One history, different approaches. J Exp Clin Cancer
Res. 33:372014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ikushima H, Todo T, Ino Y, Takahashi M,
Miyazawa K and Miyazono K: AutocrineTGF-beta signaling maintains
tumorigenicity of glioma-initiating cells through Sry-related
HMG-box factors. Cell Stem Cell. 5:504–514. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scaffidi P and Bianchi ME: Spatially
precise DNA bending is an essential activity of the sox2
transcription factor. J Biol Chem. 276:47296–47302. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu K, Lin B, Zhao M, Yang X, Chen M, Gao
A, Liu F, Que J and Lan X: The multiple roles for Sox2 in stem cell
maintenance and tumorigenesis. Cell Signal. 25:1264–1271. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kuo HY, Hsu HT, Chen YC, Chang YW, Liu FT
and Wu CW: Galectin-3 modulates the EGFR signalling-mediated
regulation of Sox2 expression via c-Myc in lung cancer.
Glycobiology. 26:155–165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gangemi RM, Griffero F, Marubbi D, Perera
M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A and Corte G:
SOX2 silencing in glioblastoma tumor-initiating cells causes stop
of proliferation and loss of tumorigenicity. Stem Cells. 27:40–48.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu W, Shen G, Shi Z, Shen F, Zheng X, Wen
L and Yang X: Brain tumour stem cells and neural stem cells: Still
explored by the same approach? J Int Med Res. 36:890–895. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ajani JA, Song S, Hochster HS and
Steinberg IB: Cancer stem cells: The promise and the potential.
Semin Oncol. 1 Suppl 42:S3–S17. 2015. View Article : Google Scholar
|
|
27
|
Islam F, Qiao B, Smith RA, Gopalan V and
Lam AK: Cancer stem cell: Fundamental experimental pathological
concepts and updates. Exp Mol Pathol. 98:184–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sharma A and Shiras A: Cancer stem
cell-vascular endothelial cell interactions in glioblastoma.
Biochem Biophys Res Commun. 473:688–692. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pearson AT, Jackson TL and Nor JE:
Modeling head and neck cancer stem cell-mediated tumorigenesis.
Cell Mol Life Sci. 73:3279–3289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eun K, Ham SW and Kim H: Cancer stem cell
heterogeneity: Origin and new perspectives on CSC targeting. BMB
Rep. 50:117–125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheng JX, Liu BL and Zhang X: How powerful
is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat
Rev. 35:403–408. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Annovazzi L, Mellai M, Caldera V, Valente
G and Schiffer D: SOX2 expression and amplification in gliomas and
glioma cell lines. Cancer Genomics Proteomics. 8:139–147.
2011.PubMed/NCBI
|
|
33
|
Dahlrot RH, Hermansen SK, Hansen S and
Kristensen BW: What is the clinical value of cancer stem cell
markers in gliomas? Int J Clin Exp Pathol. 6:334–348.
2013.PubMed/NCBI
|
|
34
|
Dahlrot RH, Hansen S, Jensen SS, Schroder
HD, Hjelmborg J and Kristensen BW: Clinical value of CD133 and
nestin in patients with glioma: A population-based study. Int J
Clin Exp Pathol. 7:3739–3751. 2014.PubMed/NCBI
|
|
35
|
Dahlrot RH: The prognostic value of
clinical factors and cancer stem cell-related markers in gliomas.
Dan Med J. 61:B49442014.PubMed/NCBI
|
|
36
|
Hermansen SK, Christensen KG, Jensen SS
and Kristensen BW: Inconsistent immunohistochemical expression
patterns of four different CD133 antibody clones in glioblastoma. J
Histochem Cytochem. 59:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
|
